Poor Sleep May Signal Faster Decline in ALS, Large Chinese Cohort Study Finds

For patients living with amyotrophic lateral sclerosis, the questions that haunt families most often concern time: how quickly will the disease progress, and what signs can be trusted to predict the road ahead? A new study from China adds a surprising candidate to the list of prognostic markers, one that costs nothing to measure and takes minutes to administer at the bedside. Sleep, or rather the lack of it, appears to carry meaningful information about survival in ALS, according to a retrospective cohort analysis published in BMC Medicine.

The research, led by a team at Hubei University of Chinese Medicine and Hubei Provincial Hospital of Traditional Chinese Medicine in Wuhan, examined whether baseline sleep quality, measured with the Pittsburgh Sleep Quality Index, was associated with a composite endpoint combining tracheostomy or death from any cause, whichever came first. The PSQI is a widely used self-report questionnaire that scores sleep quality across seven domains, including sleep duration, sleep disturbances, sleep latency, daytime dysfunction, and use of sleep medication, with total scores ranging from zero to 21 and higher values indicating worse sleep.

The investigators drew on a non-public institutional ALS registry to identify patients treated between January 2019 and May 2022. In total, 268 patients with ALS were included in the analysis, and 115 of them experienced the composite endpoint event during follow-up. The cohort was divided into three groups according to PSQI score: 117 patients scored between 0 and 5, indicating no clinically significant sleep disturbance; 92 patients scored between 6 and 10, reflecting mild disturbance; and 59 patients scored between 11 and 21, indicating moderate-to-severe sleep disturbance.

The statistical architecture of the study was deliberately thorough. Kaplan-Meier curves were used to visualize differences in endpoint-free survival across the PSQI categories, and the separation between groups was statistically significant, with a log-rank P value below 0.001. Restricted cubic spline analyses then probed the shape of the relationship between continuous PSQI scores and risk, revealing an overall increasing association with no significant evidence of non-linearity. In other words, the risk appeared to climb steadily as sleep quality worsened, rather than jumping abruptly at any particular threshold.

The centerpiece of the analysis was a multivariable Cox proportional hazards model that adjusted for an unusually comprehensive set of potential confounders: age, sex, household income, site of disease onset, forced vital capacity, total score on the revised ALS Functional Rating Scale, disease progression rate, body mass index, serum albumin, and Hamilton depression rating scale score. In this fully adjusted model, each one-point increase in PSQI score was associated with a 13 percent higher risk of tracheostomy or death, with a hazard ratio of 1.13 and a 95 percent confidence interval of 1.07 to 1.20, a result that reached statistical significance at P less than 0.001.

When patients were categorized by severity of sleep disturbance, a striking pattern emerged. Compared with patients who had no sleep disturbance, those with moderate-to-severe disturbance had a significantly higher risk of the composite endpoint, with a hazard ratio of 2.65 and a 95 percent confidence interval of 1.55 to 4.53. Mild sleep disturbance, by contrast, was not significantly associated with increased risk. This dose-response-like pattern, in which only the more severe category showed a robust signal, suggests that the association is not simply an artifact of minor, transient sleep complaints but is concentrated among patients whose sleep is substantially disrupted.

Subgroup analyses extended the picture across strata of household income, age, disease progression rate, sex, site of onset, body mass index, and albumin levels. Notably, the researchers observed significant interactions for household income and disease progression rate, indicating that the strength of the association between sleep quality and outcomes may vary depending on these patient characteristics. Sensitivity analyses were also performed to test the robustness of the findings, and the authors report that the core association held across the models they examined.

Why might poor sleep track with worse outcomes in a neurodegenerative disease that destroys motor neurons? The authors themselves urge caution on interpretation, and their reasoning is worth unpacking. Sleep disturbance in ALS is rarely an isolated complaint. It can be driven by nocturnal respiratory dysfunction, as weakening respiratory muscles lead to hypoventilation during sleep, fragmented rest, morning headaches, and daytime fatigue. It can also reflect muscle cramps, spasticity, pain, drooling, depression, and anxiety, all of which become more common as the disease advances. In this sense, the PSQI may partly function as a proxy for unmeasured nocturnal respiratory impairment or for overall disease burden rather than as an independent causal factor.

This caveat shapes the study’s practical implications. The authors explicitly state that the observational data should not be interpreted as evidence that improving sleep quality will causally improve ALS outcomes. Treating sleep problems may well improve comfort and quality of life, and clinicians already recognize the importance of screening for respiratory insufficiency and initiating noninvasive ventilation when indicated, but the new findings do not establish that sleep interventions will change the trajectory of the disease itself. What the data do support, according to the authors, is the incorporation of systematic sleep assessment into prognostic risk stratification for ALS, so that a simple questionnaire score can help clinicians identify patients who may warrant closer monitoring.

The study also highlights a broader shift in how ALS research is approaching prognosis. Traditional predictors such as site of onset, forced vital capacity, and the rate of functional decline remain the backbone of clinical staging, but researchers are increasingly probing whether patient-reported measures, nutritional markers, and psychological factors add incremental predictive value. By adjusting for depression with the Hamilton depression rating scale and for a wide range of clinical variables, the Chinese team attempted to isolate the contribution of sleep quality specifically, and the persistence of the association after such extensive adjustment lends weight to the finding, even within the limits of a single-center retrospective design.

Several limitations deserve mention when weighing the results. The cohort comprised 268 patients from one institution in Wuhan, and retrospective registry data are inherently vulnerable to measurement error and missing information. The PSQI is a subjective instrument, and objective measures such as polysomnography were not used to characterize sleep-disordered breathing directly. Residual confounding by unmeasured variables, particularly detailed nocturnal respiratory physiology, remains possible, and the authors acknowledge this directly. The composite endpoint of tracheostomy or all-cause death, while clinically meaningful, also blends different events whose timing may be influenced by patient and family decisions about invasive ventilation.

Nevertheless, the signal is compelling enough to merit follow-up. A 13 percent increase in risk per PSQI point, and a nearly threefold elevation among patients with moderate-to-severe sleep disturbance, represents one of the larger effect sizes reported for a patient-reported measure in ALS prognostication. If prospective studies in other populations confirm the association and clarify the mechanisms, sleep assessment could become a routine, low-cost component of ALS care, flagging patients whose nighttime symptoms may be the first audible warning of respiratory decline. For now, the study stands as a reminder that in a devastating disease, even the quiet hours of the night carry information that clinicians cannot afford to ignore.

Subject of Research: The association between sleep quality measured by the Pittsburgh Sleep Quality Index and the risk of tracheostomy or death in patients with amyotrophic lateral sclerosis

Article Title: Association between PSQI and composite endpoints in ALS patients: a retrospective cohort study from China

Article References: Jiang, Q., Jiang, R., Kong, W., Yang, D., Zhu, Q., Wu, M., Wan, S., Cai, F., Xu, D., & Zhou, J. (2026). Association between PSQI and composite endpoints in ALS patients: a retrospective cohort study from China. BMC Medicine. https://doi.org/10.1186/s12916-026-05263-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05263-3

Keywords: amyotrophic lateral sclerosis, sleep quality, Pittsburgh Sleep Quality Index, sleep disturbance, prognosis, retrospective cohort study, tracheostomy, all-cause mortality, motor neuron disease, Cox regression, noninvasive ventilation, BMC Medicine